Shares of Moderna slid 6.78% to $137.24 at 11:59 EST on Wednesday, after two consecutive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.2% to $12,619.70, after two consecutive sessions in a row of gains. This seems, so far, a somewhat positive trend exchanging session today.
Moderna’s last close was $147.22, 30.06% below its 52-week high of $178.50.
News about Moderna today
Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to today’s article on CNBC, "Moderna (MRNA) – Moderna was downgraded to "hold" from "buy" at Jefferies, which cited the significant runup in the drugmaker’s stock as well as high expectations surrounding its Covid-19 vaccine. "
Moderna party ending, analysts caution before shot approval. According to today’s article on Bloomberg Quint, "Moderna’s valuation may be at risk if retail interest wanes as new vaccines become a reality. ", "Moderna now has nine buys, seven holds and two sell ratings, according to data compiled by Bloomberg."
Moderna’s sales growth is 1428.1% for the current quarter and 13065.3% for the next. The company’s growth estimates for the present quarter is a negative 48.6% and positive 565.7% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s Stock Top and Bottom Yearly Value
Moderna’s stock is valued at $137.24 at 11:59 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.
Moderna’s Moving Average
Moderna’s value is way higher than its 50-day moving average of $108.35 and way higher than its 200-day moving average of $78.59.
Previous days news about Moderna
Moderna says U.S. to buy 100 million additional vaccine doses. According to Bloomberg Quint on Fri Dec 11, "Moderna Inc. said the U.S. government exercised its option to buy 100 million additional doses of the company’s coronavirus vaccine candidate, doubling the amount of the shot it initially committed to purchase and easing concern that the U.S. could be left with a vaccine shortfall.", "Moderna shares gained 2.6% in late trading in New York. "
Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to The Wall Street Journal on Tue Dec 15, "-Shares of the vaccine maker Moderna were down 1% premarket. "
Moderna vaccine found safe, effective ahead of key FDA review. According to Bloomberg Quint on Tue Dec 15, "Moderna’s vaccine isn’t yet approved in any other countries and hasn’t yet been used on anyone outside of a clinical trial.", "Both the Moderna vaccine and the Pfizer vaccine are based on messenger RNA technology that hasn’t been previously used in inoculations. "
Moderna vaccine found safe, effective before key FDA review. According to Bloomberg Quint on Tue Dec 15, "Between Pfizer and Moderna, Operation Warp Speed officials have said 20 million people in the U.S. are expected to get their first shots by year-end.", "Both the Moderna Pfizer products are based on messenger RNA technology that hasn’t been previously used in human vaccines. "
Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to MarketWatch on Tue Dec 15, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company’s COVID-19 vaccine candidate is “highly effective” at preventing infections with the coronavirus. "
Canada to receive early access to Moderna Covid-19 vaccine. According to Business Insider on Tue Dec 15, "The Moderna vaccine would be the first delivered through the end-to-end COVID-19 logistics services contract awarded to FedEx Express Canada and Innomar Strategies Inc.", "The logistical planning for the delivery of Moderna doses is complete, and shipments to Canada could begin within 48 hours of regulatory approval."
Moderna to offer covid shots to volunteers who got placebo. According to Bloomberg Quint on Tue Dec 15, "Moderna Inc. is preparing to offer its Covid-19 shot to trial participants who received a placebo in the final-stage study once the vaccine is authorized for emergency use in the U.S.", "Ray Jordan, a Moderna spokesman, confirmed the letter was being prepared."